NRXBFNUREXONE BIOLOGIC INC

About NUREXONE BIOLOGIC INC (NRXBF)

NUREXONE BIOLOGIC INC (NRXBF) is a Biotechnology company headquartered in Calgary, AB, Canada whose shares trade over-the-counter on the OTCQB tier.

NurExone Biologic Inc. is a TSXV and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered Central Nervous System injuries. The Company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA and European agency, European Medicines Agency. The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Products and services

The Company operates in two business lines: 1. Development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). 2. Monetization of its proprietary ExoTherapy technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications.

NRXBF key facts

Ticker symbol

NRXBF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Calgary, AB, Canada

Country of incorporation

CA

Year of incorporation

2011

Employees

18

Estimated market cap

$35.74M (as of Apr 16, 2025)

Shares outstanding

74,464,675

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

NUREXONE BIOLOGIC INC leadership

• Dr. Lior Shaltiel — CEO
• Eran Ovadya — CFO
• Yoram Drucker — Vice President
• Allison Kaufman — Counsel

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with N